Real-World Outcomes and Healthcare Utilization of Lanadelumab in Spain: Insights from First Cohort of Difficult-to-Treat Hereditary Angioedema Cases
February 2025
in “
Allergies
”
TLDR Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.
This study assessed the real-world impact of lanadelumab on four Caucasian female patients with difficult-to-treat hereditary angioedema (HAE) in Spain. Lanadelumab treatment led to a 75.3% reduction in hospital visits and a 94.1% decrease in angioedema episodes. The use of on-demand icatibant treatment was reduced by 61%, and quality of life scores improved significantly from 62.2 to 99.5. No significant adverse effects were reported. The findings suggest that lanadelumab is an effective long-term prophylactic treatment, reducing healthcare utilization and improving patient quality of life, although further research with larger cohorts is needed to confirm these results.
